Fort Washington Investment Advisors Inc. OH Sells 379,989 Shares of Haemonetics Corporation $HAE

Fort Washington Investment Advisors Inc. OH reduced its holdings in Haemonetics Corporation (NYSE:HAE) by 45.7% during the 3rd quarter, HoldingsChannel reports. The firm owned 450,936 shares of the medical instruments supplier’s stock after selling 379,989 shares during the quarter. Fort Washington Investment Advisors Inc. OH’s holdings in Haemonetics were worth $47,484,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently added to or reduced their stakes in the business. Dimensional Fund Advisors LP grew its holdings in Haemonetics by 21.3% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,326,057 shares of the medical instruments supplier’s stock valued at $74,731,000 after buying an additional 233,119 shares during the last quarter. Bank of America Corp DE bought a new position in Haemonetics in the 2nd quarter worth approximately $33,326,000. William Blair Investment Management LLC bought a new position in Haemonetics in the 2nd quarter worth approximately $24,906,000. Bank of New York Mellon Corp acquired a new position in shares of Haemonetics during the second quarter worth approximately $21,566,000. Finally, London Co. of Virginia lifted its holdings in shares of Haemonetics by 33.9% during the first quarter. London Co. of Virginia now owns 352,807 shares of the medical instruments supplier’s stock worth $19,884,000 after buying an additional 89,242 shares during the last quarter. Institutional investors own 99.67% of the company’s stock.

Haemonetics Trading Down 0.6%

Shares of HAE opened at $120.99 on Thursday. The stock has a fifty day moving average price of $104.17 and a two-hundred day moving average price of $80.91. The company has a debt-to-equity ratio of 1.40, a quick ratio of 1.91 and a current ratio of 3.08. The company has a market cap of $5.51 billion, a price-to-earnings ratio of 24.30, a PEG ratio of 2.43 and a beta of 0.61. Haemonetics Corporation has a 52-week low of $48.55 and a 52-week high of $123.77.

Haemonetics (NYSE:HAE) last released its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $1.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.08 by $0.06. Haemonetics had a return on equity of 27.55% and a net margin of 7.12%. The business had revenue of $339.38 million during the quarter, compared to analysts’ expectations of $327.86 million. During the same period in the previous year, the business posted $1.10 earnings per share. The firm’s revenue for the quarter was up 5.5% compared to the same quarter last year. Analysts predict that Haemonetics Corporation will post 5.29 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the company. JPMorgan Chase & Co. increased their price objective on Haemonetics from $62.00 to $86.00 and gave the company a “neutral” rating in a research report on Friday, August 7th. Raymond James Financial boosted their target price on shares of Haemonetics from $105.00 to $125.00 and gave the stock an “outperform” rating in a research report on Thursday, September 3rd. Mizuho raised their price target on shares of Haemonetics from $95.00 to $140.00 and gave the stock an “outperform” rating in a research report on Friday, October 9th. Weiss Ratings upgraded shares of Haemonetics from a “hold (c-)” rating to a “hold (c)” rating in a report on Tuesday, August 11th. Finally, Robert W. Baird boosted their price objective on shares of Haemonetics from $96.00 to $119.00 and gave the stock an “outperform” rating in a report on Friday, August 21st. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, Haemonetics has an average rating of “Moderate Buy” and an average price target of $110.00.

About Haemonetics

Haemonetics Corporation (NYSE: HAE) is a medical technology company that develops and supplies products and software for blood management. Its solutions are used to collect, process, manage and analyze blood and blood components, helping healthcare providers and blood and plasma collection organizations improve the availability, safety and efficiency of transfusion-related care.

The company’s portfolio includes plasma and blood component collection systems, disposable collection and processing kits, surgical blood recovery and autotransfusion systems, and technologies used to assess coagulation and hemostasis.